Desipramine treatment for cocaine dependence in buprenorphine- or methadone-treated patients: Baseline urine results as predictor of response

American Journal on Addictions

Volumn 14, Issue 1, 2005, Pages 8-17

  Kosten, Thomas ^a   Sofuoglu, Mehmet ^a   Poling, James ^a   Gonsai, Kishor ^a   Oliveto, Alison ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; COCAINE; DESIPRAMINE; METHADONE; OPIATE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; COCAINE DEPENDENCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; URINE;

ADRENERGIC UPTAKE INHIBITORS; ADULT; BUPRENORPHINE; COCAINE; COCAINE-RELATED DISORDERS; DESIPRAMINE; DOPAMINE UPTAKE INHIBITORS; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; NARCOTIC ANTAGONISTS; PLACEBOS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME; URINALYSIS;

EID: 13444310808     PISSN: 10550496     EISSN: None     Source Type: Journal    
DOI: 10.1080/10550490590899817     Document Type: Article

References (27)

1. Lavori PW, Bloch DA, Bridge PT, et al. Plans, designs, and analyses for clinical trials of anti-cocaine medications: where we are today. NIDA/VA/SU working group on design and analysis. J Clin Psychopharmacol. 1999;19:246-256.
2. Carroll KM, Power ME, Bryant K, et al. One-year follow-up status of treatment-seeking cocaine abusers: psychopathology and dependence severity as predictors of outcome. J Nerv Ment Dis. 1993;181:71-79.
3. Siqueland L, Crits-Christoph P, Gallop R, et al. Retention in psychosocial treatment of cocaine dependence: predictors and impact on outcome. Am J Addict. 2002;11:24-40.
4. Moeller FG, Dougherty DM, Barratt ES, et al. The impact of impulsivity on cocaine use and retention in treatment. J Subst Abuse Treat. 2001;21:193-198.
5. McMahon RC, Kouzekanani K, Malow RM. A comparative study of cocaine-treatment completers and dropouts. J Subst Abuse Treat. 1999;16:17-22.
6. Reiber C, Ramirez A, Parent D, et al. Predicting treatment success at multiple timepoints in diverse patient populations of cocaine-dependent individuals. Drug Alcohol Depend. 2002;68:35-48.
7. Alterman AI, Kampman K, Boardman CR, et al. A cocaine-positive baseline urine predicts outpatient treatment attrition and failure to attain initial abstinence. Drug Alcohol Depend. 1997;46:79-85.
8. Ehrman RN, Robbins SJ, Cornish JW. Results of a baseline urine test predict levels of cocaine use during treatment. Drug Alcohol Depend. 2001;62:1-7.
9. Oliveto AH, Feingold A, Schottenfeld R, et al. Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs. methadone. Arch Gen Psychiatry. 1999;56:812-820.
10. Kosten TR, Kleber HD, Morgan C. Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci. 1989;44:887-892.
11. Schottenfeld RS, Pakes J, Ziedonis D, et al. Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans. Biol Psychiatry. 1993;34:66-74.
12. Kosten TR, Morgan CM, Falcione J, et al. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch Gen Psychiatry. 1992;49:894-898.
13. McGlothlin WH, Anglin MD. Long-term follow-up of clients with high- and low-dose methadone programs. Arch Gen Psychiatry. 1931;31:1055-1063.
14. Hargreaves WA. Methadone Dose and Duration of Treatment: Research on the Treatment of Narcotic Addiction State of the Art. Rockville, Md.: NIDA, Alcohol, Drug Abuse, and Mental Health Services; 1983.
15. Hatziandreu EJ, Sisk JE, Hughes R. The effectiveness of drug abuse treatment: implications for controlling AIDS/HIV infection. Office of Technology Assessment Series on AIDS-Related Issues; 1990.
16. Kosten TR, Schottenfeld RS, Ziedonis D, et al. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis. 1993;181:358-364.
17. Spitzer RL, Williams JBW, Givvons M, et al. Structural Clinical Interview for DSM-III-R. Washington, DC: American Psychiatric Association Press; 1990.
18. McLellan AT, Cacciola J, Kushner H, et al. The fifth edition of the Addiction Severity Index: cautions, additions, and normative data. J Subst Abuse. 1992;9:461-480.
19. Bryk AS, Raudenbush SW. Application of hierarchical linear models to assessing change. Psychol Bull. 1987;101:147-158.
20. Gibbons RD, Hedeker D, Elkin I, et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data: application to the NIMH Treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry. 1993;50:739-750.
21. Strain EC, Stitzer ML, Liebson IA, et al. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry. 1994;151:1025-1030.
22. Schottenfeld RS, Pakes JR, Oliveto A, et al. Buprenorphine vs. methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry. 1997;54:713-720.
23. George TP, Chawarski MC, Pakes J, et al. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol Psychiatry. 2000;47:1080-1086.
24. Compton PA, Ling W, Charuvastra VC, et al. Buprenorphine as a pharmacotherapy for cocaine abuse: a review of the evidence. J Addict Dis. 1995;14:97-114.
25. Arndt IO, Dorozynsky L, Woody GR, et al. Desipramine treatment of cocaine dependence in methadone-maintained patients. Arch Gen Psychiatry. 1992;49:888-893.
26. Kosten TR, Gawin FH, Morgan CH, et al. Evidence for altered desipramine disposition in methadone-maintained patients treated for cocaine abuse. Am J Drug Alcohol Abuse. 1990;16:329-336.
27. Sofuoglu M, Gonzalez J, Poling J, Kosten TR. Prediction of treatment outcome by baseline urine cocaine results and self-reported cocaine use for cocaine and opioid dependence. Am J Drug Alcohol Abuse. 2003;29(4):713-727.